AstraZeneca (LON:AZN) Receives “Sell” Rating from Deutsche Bank Aktiengesellschaft

Deutsche Bank Aktiengesellschaft reiterated their sell rating on shares of AstraZeneca (LON:AZN – Free Report) in a report issued on Tuesday morning, MarketBeat Ratings reports. Several other brokerages have also recently weighed in on AZN. Jefferies Financial Group reaffirmed a hold rating and set a £110 ($140.94) price objective on shares of AstraZeneca in a […]

Leave a Reply

Your email address will not be published.

Previous post Edwards scores 37 as Timberwolves overcome 22-point first-half deficit to thump Clippers
Next post Inozyme Pharma’s (INZY) Outperform Rating Reaffirmed at Wedbush